The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes : a randomised, double-blind, placebo-controlled crossover trial. / Heimbürger, Sebastian M.N.; Hoe, Bjørn; Nielsen, Chris N.; Bergmann, Natasha C.; Hartmann, Bolette; Holst, Jens J.; Vilsbøll, Tina; Dejgaard, Thomas F.; Christensen, Mikkel B.; Knop, Filip K.

In: Diabetologia, 2021.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Heimbürger, SMN, Hoe, B, Nielsen, CN, Bergmann, NC, Hartmann, B, Holst, JJ, Vilsbøll, T, Dejgaard, TF, Christensen, MB & Knop, FK 2021, 'The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial', Diabetologia. https://doi.org/10.1007/s00125-021-05547-8

APA

Heimbürger, S. M. N., Hoe, B., Nielsen, C. N., Bergmann, N. C., Hartmann, B., Holst, J. J., Vilsbøll, T., Dejgaard, T. F., Christensen, M. B., & Knop, F. K. (2021). The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial. Diabetologia. https://doi.org/10.1007/s00125-021-05547-8

Vancouver

Heimbürger SMN, Hoe B, Nielsen CN, Bergmann NC, Hartmann B, Holst JJ et al. The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial. Diabetologia. 2021. https://doi.org/10.1007/s00125-021-05547-8

Author

Heimbürger, Sebastian M.N. ; Hoe, Bjørn ; Nielsen, Chris N. ; Bergmann, Natasha C. ; Hartmann, Bolette ; Holst, Jens J. ; Vilsbøll, Tina ; Dejgaard, Thomas F. ; Christensen, Mikkel B. ; Knop, Filip K. / The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes : a randomised, double-blind, placebo-controlled crossover trial. In: Diabetologia. 2021.

Bibtex

@article{72ad6a0187dc4a6f8cda18596b576347,
title = "The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial",
abstract = "Aims/hypothesis: Type 1 diabetes is characterised by reduced glucagon response to hypoglycaemia, increasing the risk of insulin treatment-associated hypoglycaemia known to hamper glycaemic control. We previously reported a glucagonotropic effect of exogenous glucose-dependent insulinotropic polypeptide (GIP) during insulin-induced hypoglycaemia in individuals with type 1 diabetes. Here we investigate the effect of a 6-day s.c. GIP infusion on time in glycaemic range as assessed by continuous glucose monitoring (CGM) in individuals with type 1 diabetes. Methods: In a randomised, placebo-controlled, double-blind crossover study, time in glycaemic range (assessed by double-blinded CGM) was evaluated in 20 men with type 1 diabetes (18–75 years, stable insulin treatment ≥3 months, diabetes duration 2–15 years, fasting plasma C-peptide below 200 pmol/l, BMI 20–27 kg/m2, HbA1c <69 mmol/mol [8.5%]) during two × 6 days of continuous s.c. GIP (6 pmol kg−1 min−1) and placebo (saline [154 mmol/l NaCl]) infusion, respectively, with an interposed 7-day washout period. The primary outcome was glycaemic time below range, time in range and time above range. Results: There were no significant differences in time below range (<3.9 mmol/l, p = 0.53) or above range (>10 mmol/l, p = 0.32) during night-time or daytime, in mean glucose, or in hypoglycaemic events as assessed by CGM. GIP altered neither self-reported hypoglycaemia nor safety measures. Compared with placebo, GIP significantly increased time in tight range (3.9–7.8 mmol/l) during daytime (06:00–23:59 hours) by [mean ± SEM] 11.2 ± 5.1% [95% CI 0.41, 21.9] (p = 0.02). Conclusions/interpretation: Six-day s.c. GIP infusion in men with type 1 diabetes did not procure convincing effect on overall time in range, but increased time in tight glycaemic range during daytime by ~2 h per day. Trial registration: ClinicalTrials.gov NCT03734718. Funding: The study was funded by grants from The Leona M. and Harry B. Helmsley Charitable Trust and Aase og Ejnar Danielsens Fond. Graphical abstract: [Figure not available: see fulltext.]",
keywords = "Adipose tissue, Continuous glucose monitoring, GIP, Glucose-dependent insulinotropic polypeptide, Glycaemic control, Glycaemic time in range, Hypoglycaemia, Hypoglycaemic events, Insulin resistance, Insulin sensitivity",
author = "Heimb{\"u}rger, {Sebastian M.N.} and Bj{\o}rn Hoe and Nielsen, {Chris N.} and Bergmann, {Natasha C.} and Bolette Hartmann and Holst, {Jens J.} and Tina Vilsb{\o}ll and Dejgaard, {Thomas F.} and Christensen, {Mikkel B.} and Knop, {Filip K.}",
note = "Publisher Copyright: {\textcopyright} 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.",
year = "2021",
doi = "10.1007/s00125-021-05547-8",
language = "English",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer",

}

RIS

TY - JOUR

T1 - The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes

T2 - a randomised, double-blind, placebo-controlled crossover trial

AU - Heimbürger, Sebastian M.N.

AU - Hoe, Bjørn

AU - Nielsen, Chris N.

AU - Bergmann, Natasha C.

AU - Hartmann, Bolette

AU - Holst, Jens J.

AU - Vilsbøll, Tina

AU - Dejgaard, Thomas F.

AU - Christensen, Mikkel B.

AU - Knop, Filip K.

N1 - Publisher Copyright: © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

PY - 2021

Y1 - 2021

N2 - Aims/hypothesis: Type 1 diabetes is characterised by reduced glucagon response to hypoglycaemia, increasing the risk of insulin treatment-associated hypoglycaemia known to hamper glycaemic control. We previously reported a glucagonotropic effect of exogenous glucose-dependent insulinotropic polypeptide (GIP) during insulin-induced hypoglycaemia in individuals with type 1 diabetes. Here we investigate the effect of a 6-day s.c. GIP infusion on time in glycaemic range as assessed by continuous glucose monitoring (CGM) in individuals with type 1 diabetes. Methods: In a randomised, placebo-controlled, double-blind crossover study, time in glycaemic range (assessed by double-blinded CGM) was evaluated in 20 men with type 1 diabetes (18–75 years, stable insulin treatment ≥3 months, diabetes duration 2–15 years, fasting plasma C-peptide below 200 pmol/l, BMI 20–27 kg/m2, HbA1c <69 mmol/mol [8.5%]) during two × 6 days of continuous s.c. GIP (6 pmol kg−1 min−1) and placebo (saline [154 mmol/l NaCl]) infusion, respectively, with an interposed 7-day washout period. The primary outcome was glycaemic time below range, time in range and time above range. Results: There were no significant differences in time below range (<3.9 mmol/l, p = 0.53) or above range (>10 mmol/l, p = 0.32) during night-time or daytime, in mean glucose, or in hypoglycaemic events as assessed by CGM. GIP altered neither self-reported hypoglycaemia nor safety measures. Compared with placebo, GIP significantly increased time in tight range (3.9–7.8 mmol/l) during daytime (06:00–23:59 hours) by [mean ± SEM] 11.2 ± 5.1% [95% CI 0.41, 21.9] (p = 0.02). Conclusions/interpretation: Six-day s.c. GIP infusion in men with type 1 diabetes did not procure convincing effect on overall time in range, but increased time in tight glycaemic range during daytime by ~2 h per day. Trial registration: ClinicalTrials.gov NCT03734718. Funding: The study was funded by grants from The Leona M. and Harry B. Helmsley Charitable Trust and Aase og Ejnar Danielsens Fond. Graphical abstract: [Figure not available: see fulltext.]

AB - Aims/hypothesis: Type 1 diabetes is characterised by reduced glucagon response to hypoglycaemia, increasing the risk of insulin treatment-associated hypoglycaemia known to hamper glycaemic control. We previously reported a glucagonotropic effect of exogenous glucose-dependent insulinotropic polypeptide (GIP) during insulin-induced hypoglycaemia in individuals with type 1 diabetes. Here we investigate the effect of a 6-day s.c. GIP infusion on time in glycaemic range as assessed by continuous glucose monitoring (CGM) in individuals with type 1 diabetes. Methods: In a randomised, placebo-controlled, double-blind crossover study, time in glycaemic range (assessed by double-blinded CGM) was evaluated in 20 men with type 1 diabetes (18–75 years, stable insulin treatment ≥3 months, diabetes duration 2–15 years, fasting plasma C-peptide below 200 pmol/l, BMI 20–27 kg/m2, HbA1c <69 mmol/mol [8.5%]) during two × 6 days of continuous s.c. GIP (6 pmol kg−1 min−1) and placebo (saline [154 mmol/l NaCl]) infusion, respectively, with an interposed 7-day washout period. The primary outcome was glycaemic time below range, time in range and time above range. Results: There were no significant differences in time below range (<3.9 mmol/l, p = 0.53) or above range (>10 mmol/l, p = 0.32) during night-time or daytime, in mean glucose, or in hypoglycaemic events as assessed by CGM. GIP altered neither self-reported hypoglycaemia nor safety measures. Compared with placebo, GIP significantly increased time in tight range (3.9–7.8 mmol/l) during daytime (06:00–23:59 hours) by [mean ± SEM] 11.2 ± 5.1% [95% CI 0.41, 21.9] (p = 0.02). Conclusions/interpretation: Six-day s.c. GIP infusion in men with type 1 diabetes did not procure convincing effect on overall time in range, but increased time in tight glycaemic range during daytime by ~2 h per day. Trial registration: ClinicalTrials.gov NCT03734718. Funding: The study was funded by grants from The Leona M. and Harry B. Helmsley Charitable Trust and Aase og Ejnar Danielsens Fond. Graphical abstract: [Figure not available: see fulltext.]

KW - Adipose tissue

KW - Continuous glucose monitoring

KW - GIP

KW - Glucose-dependent insulinotropic polypeptide

KW - Glycaemic control

KW - Glycaemic time in range

KW - Hypoglycaemia

KW - Hypoglycaemic events

KW - Insulin resistance

KW - Insulin sensitivity

U2 - 10.1007/s00125-021-05547-8

DO - 10.1007/s00125-021-05547-8

M3 - Journal article

C2 - 34405256

AN - SCOPUS:85112766469

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

ER -

ID: 276655418